Mass­a­chu­setts Gov­er­nor Char­lie Bak­er un­veils a $500M pro­gram to keep its big biotech hub boom­ing

The biotech hub in Boston/Cam­bridge is boom­ing, and Gov­er­nor Char­lie Bak­er is ad­vo­cat­ing a $500 mil­lion pro­gram for the next five years aimed at keep­ing the good times rolling.

It’s set up as a suc­ces­sor to for­mer Gov­er­nor De­val Patrick’s high-pro­file $1 bil­lion plan, un­veiled in 2008, to help spark growth in the life sci­ences field. Bak­er is propos­ing to spend $295 mil­lion on in­fra­struc­ture col­lab­o­ra­tions in the state, while ear­mark­ing $150 mil­lion for tax in­cen­tives de­signed to lever­age the cre­ation of new jobs.

While cater­ing to po­lit­i­cal con­stituen­cies around the state to make it more palat­able to all law­mak­ers, the gov­er­nor’s pro­pos­al comes af­ter an era of sharp growth cen­tered in Cam­bridge and rip­pling through the big Boston metro area. Just this morn­ing a new re­port on key in­dus­try trends from EY high­light­ed the re­gion’s con­tin­ued abil­i­ty to at­tract bil­lions in in­vest­ment cap­i­tal for star­tups.

Bob Cough­lin

Be­fore De­val Patrick came along with his $1 bil­lion plan, the life sci­ences in­dus­try had grown deeply en­trenched in the state, build­ing a close re­la­tion­ship be­tween Har­vard and MIT and the life sci­ences busi­ness­es like Bio­gen that got start­ed here. The biotech in­dus­try en­joys the role of one of the most fa­vored groups in the state, and lo­cal ex­ecs lined up to praise the new ini­tia­tive and the politi­cian who will pro­mote it.

“Ver­tex calls Mass­a­chu­setts home be­cause the Com­mon­wealth is the glob­al leader in life sci­ences, and this leg­is­la­tion, cou­pled with the Gov­er­nor’s tremen­dous sup­port for the in­dus­try, will pro­vide the tools nec­es­sary to main­tain our lead­er­ship po­si­tion,” said Ver­tex CEO Jef­frey Lei­den in a state­ment.

Mass­Bio chief Bob Cough­lin loud­ly ap­plaud­ed the pro­gram, not­ing:

For Mass­a­chu­setts res­i­dents Gov­er­nor Bak­er’s ac­tions mean more high pay­ing jobs in all cor­ners of the state for years to come. For pa­tients of the world, it means more break­through cures and treat­ments will reach them faster.

Eco­nom­ic de­vel­op­ment pro­grams like these are cer­tain­ly wel­comed with a smile. But states like Flori­da that tried to ig­nite their own biotech booms have come away with lit­tle to show for it. Cal­i­for­nia’s stem cell pro­gram in­vest­ed bil­lions on the field, but that wave re­ced­ed with­out cre­at­ing much in the way of vi­able new com­pa­nies and jobs.

Mass­a­chu­setts, though, gets to help fu­el a fire that’s al­ready burn­ing bright­ly.

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

Tony Coles, Cerevel CEO

Cerev­el takes the pub­lic of­fer­ing route, with a twist — rais­ing big mon­ey thanks to ri­val da­ta

As public biotechs seek to climb out of the bear market, a popular strategy to raise cash has been through public offerings on the heels of positive data. But one proposed raise Wednesday appeared to take advantage not of a company’s own data, but those from a competitor.

Cerevel Therapeutics plans to raise $250 million in a public offering and another $250 million in debt, the biotech announced Wednesday afternoon, even though it did not report any news on its pipeline. However, the move comes days after rival Karuna Therapeutics touted positive Phase III data in schizophrenia, a field where Cerevel is pursuing a similar program.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: Amid mas­sive re­struc­tur­ing, Bio­gen looks to re­duce phys­i­cal pres­ence in Boston

Biogen is putting a sizable chunk of office and research space in Kendall Square and Weston, MA up for sublease, marking another big change as the biotech grapples with the aftershock of a disastrous and controversial rollout for its Alzheimer’s drug.

The subbleases are “part of Biogen’s overall implementation of the ‘Future of Work,’ which is allowing us to optimize our footprint and reduce the amount of space we occupy, taking into consideration new elements such as the hybrid work model,” Biogen spokesperson Ashleigh Koss wrote in a statement to Endpoints News, adding that the company has had subleases across several buildings for years.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Who are the women blaz­ing trails in bio­phar­ma R&D? Nom­i­nate them for End­points' 2022 spe­cial re­port

Over the past three years, Endpoints News has spotlighted 60 women who have blazed trails and supercharged R&D across the biopharma world. And judging from the response we’ve received, to both our special reports and live events, telling their stories — including any obstacles they may have had to overcome — has inspired our readers in many different ways.

But change takes time, and the fact remains that women are still underrepresented at the upper ranks of the drug-making world.

Bernat Olle, Vedanta Biosciences CEO

Cit­ing 'chal­leng­ing eco­nom­ic en­vi­ron­ment,' PhI­II-ready mi­cro­bio­me biotech lays off 20% of staffers

The market downturn isn’t just sweeping up public biotechs.

Vedanta Biosciences, a developer of oral drugs derived from the human microbiome, is laying off about 20% of its staff — an unfortunately common occurrence these days. But CEO Bernat Olle took the unusual step of sharing the decision on LinkedIn and offering to connect the employees being let go with any company that’s hiring in their areas.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Hervé Affagard, MaaT Pharma CEO

One year in­to clin­i­cal hold, FDA has more ques­tions about 'pooled' mi­cro­bio­me ther­a­py

The FDA is still wary about a trial testing a microbiome therapy in patients with steroid-resistant acute graft-versus-host disease (aGVHD).

A year after MaaT Pharma’s IND application in the US was first met with a clinical hold, the French biotech said the agency is maintaining the hold. The crux of the matter, MaaT suggested, has to do with the way it puts together its drug candidate, which is administered as an enema (i.e. an injection of fluid into the bowel).

Pfiz­er launch­es re­bate pro­gram for rare dis­ease pa­tients who have to stop tak­ing Panzy­ga

Pfizer is launching its second-ever rebate program, this time for Panzyga, its treatment for a rare neurological disease of the peripheral nerves.

The program began last month, according to STAT which first reported the news, and offers a refund of out-of-pocket costs for patients who must discontinue their course before the fifth treatment for “clinical reasons.”

Panzyga was approved back in 2018 to treat primary immunodeficiency (PI) in patients two years and older and chronic immune thrombocytopenia (cITP) in adults. It has since picked up an indication in chronic inflammatory demyelinating polyneuropathy (CIDP), a condition that’s characterized by weakness of the arms or legs, tingling or numbness, and a loss of deep tendon reflexes, according to the NIH.

Horizon's back-to-school campaign for children with cystinosis includes an all about me poster as part of a care package box.

Hori­zon read­ies kids and fam­i­lies for back to school with week­long ac­tiv­i­ties around rare dis­ease cysti­nosis

Going back to school is usually a bumpy readjustment from summer freedom for all kids, but especially for kids with chronic health conditions. Horizon Therapeutics is hoping to help smooth the way for some who have the rare disease cystinosis. Cystinosis is a genetic disease that causes the amino acid cystine to build up in different tissues and organs.

The “Gear Up” for school campaign is running all week with different online and at-home events and activities for families and children with cystinosis. Each family who signed up receives a care package mailed to their home including an activity coloring book “Michael’s Show-and-Tell.” The book tells Michael’s story about living with cystinosis while offering kids matching, coloring and finding object games along with information.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.

Phar­mas spend mil­lions on di­a­betes ad­ver­tis­ing, but few pa­tients can re­call brand names — sur­vey

While many Big Pharma diabetes brands spend millions of dollars on TV ads every year, most people with type 2 diabetes don’t recognize specific drug brand names, according to a new study.

No brand garnered more than 30% recognition in Phreesia Life Science’s latest in-office patient survey of more than 4,000 adults with type 2 diabetes. Eli Lilly’s Trulicity topped the list as the most recognized brand with 29% of those surveyed recalling it, followed by Boehringer Ingelheim and Lilly’s Jardiance at 27% and Merck’s Januvia and Novo Nordisk tying for the third spot with 24%. Meanwhile, 76% of the patients surveyed were familiar with the generic treatment metformin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.